At a press conference at SABCS 2012, Prof David Cameron presents data on the BEATRICE study, patients who received one year of bevacizumab in addition to chemotherapy for the postsurgical treatment of triple-negative breast cancer had no statistically significant improvement in invasive disease-free survival compared with patients treated with chemotherapy alone, according to the primary results of the phase III study.

Read more in ecancerNews.